Implementing a clinical decision support system (CDSS) for chronic swelling in NSW public clinics

Not Applicable

• Conditions: ymphoedema; Lymphoedema; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system

• Registration Number: ACTRN12622000601730
• Lead Sponsor: Sydney Health Partners

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-22
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

There are two participant groups.
i) Clinicians registered/registerable as lymphoedema therapists as per the Australasian Lymphology Association guidelines employed in the participating local health districts
ii) Patients attending lymphoedema services in the local health districts who have been assessed (including circumference measurements on at least three other occasions.

Exclusion Criteria

The CPI, although fitting the criteria for inclusion as a clinician participant has been excluded based on conflict of interest.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Implementation, (including uptake, impact, barriers and facilitators) of the CDSS will be evaluated.<br>Barriers, facilitators and impact will be explored during the semi-structured interviews and NOMAD-23 questionnaire at the end of each stage.<br><br>[The questionnaire will be sent out on completion of the four month trial and the semi-structured interviews will be booked approximately 2 weeks after trial completion.]

Secondary Outcome Measures

Name	Time	Method
Patient activation <br>Measured using a patient activation measure (PAMS-13) adapted for this population (LSM-PAMS-13). This will be provided to patients during Stage 1 pre-and post the introduction of Lymbase,[This will be provided to patients during Stage 1 only with 20 patients recruited in the month prior to the trial and following up these patients at any point that they return during the trial period. ];Uptake will be evaluated over a two week period. This snapshot will compare the number of occasions of service on the eMR schedule against the number of sessions entered on Lymbase. During this period an audit will also be undertaken to evaluate feature utilisation within the platform to see which elements are the most relevant to clinicians. An audit tool based on the inputs for the system has been developed.<br>[The two week snapshot will occur in the third or fourth month of the 4 month trial (ensuring a time is selected without staff absence). ]